Department of Zoology, College of Sciences, King Saud University (KSU), P.O. Box 2455, Riyadh 11451, Saudi Arabia.
Research Department of Chemistry, Nehru Memorial College (Affiliated to Bharathidasan University), Puthanampatti - 621007, Tiruchirappalli District, Tamil Nadu, India.
J Infect Public Health. 2020 Dec;13(12):1951-1960. doi: 10.1016/j.jiph.2020.09.017. Epub 2020 Oct 21.
This work is development of new hydantoin molecules as treatment of potential antibacterial and antifungal activity against clinical pathogens causing infectious disease. Synthesized compounds were evaluated in molecular docking studies, the most effective compound is used to dock against the targets of 1U1Z, and 1AI9 kinases, to evaluate its binding affinity, hoping to rationalize and obtain potent of antibacterial, antifungal agents.
The FTIR, H &C NMR, and mass spectra were used to conform new molecules and their evaluation of antimicrobial activity. Gram-negative bacteria of Pseudomonas aeruginosa (ATCC-27853), Klebsiella pneumoniae (recultured) and Escherichia coli (ATCC-25922), and gram-positive bacteria of Enterococcus faecalis (recultured) and Staphylococcus aureus (ATCC-25923) were evaluated for all compounds. The in vitro antifungal activity was evaluated against Cryptococcus neoformans (recultured), Candida albicans (recultured), Aspergillus niger, Microsporum audouinii (recultured) and Aspergillus fumigatus (recultured) for all synthesized compounds.
Antibacterial screening, we identified highly active antimicrobial agents for this study for example; gram-negative bacterial screening of 3g was highly (MIC: 0.25 μg/mL) active in contradiction of P. aeruginosa, whereas bacterial screening of 3e and 3h were more active (MIC: 2 μg/mL) in contradiction of K. pneumoniae and also 3g was more (MIC: 2 μg/mL) active in contradiction of E. faecalis than standard ciprofloxacin. Antifungal activity, the 3b was more active (MIC: 0.25 μg/mL) against C. albicance,3g (MIC: 2 μg/mL) and 3h (MIC: 4 μg/mL) were more potential of A. funigatus, and the compound 3c was highly (MIC: 4 μg/mL) active on M. audouinii than clotrimazole. Molecular docking studies also supported the new finding of potent antimicrobial agents, the compound 3g, 3b, and controls Ciprofloxacin, Clotrimazole were checked again proteins 1U1Z and 1AI9 by Autodock Vina program. The compound 3g was highest binding affinity (-8.4 kcal/mol) than ciprofloxacin (-8.2 kcal/mol) in 1U1Z protein and the compound 3b was highest binding affinity (-8.8 kcal/mol) than clotrimazole (-6.8 kcal/mol) in 1AI9 protein respectively.
A novel set of imidazolidine-2,4-dione compounds 3a-h have synthesized and characterized successfully. The screening of antimicrobial activity shows that all compounds possess antimicrobial activities. In addition, the objective of the study was succeeded with a few of the promising molecules, which are proving to be a potential treatment of bacterial infection candidates.
本工作旨在开发新的海因类分子,作为治疗临床病原体引起的感染性疾病的潜在抗菌和抗真菌活性的治疗方法。合成的化合物在分子对接研究中进行了评估,最有效的化合物用于对接 1U1Z 和 1AI9 激酶的靶标,以评估其结合亲和力,希望能合理设计并获得有效的抗菌、抗真菌药物。
使用傅里叶变换红外光谱(FTIR)、氢核磁共振(H & C NMR)和质谱来确认新分子及其抗菌活性的评估。对革兰氏阴性菌铜绿假单胞菌(ATCC-27853)、肺炎克雷伯菌(再培养)和大肠杆菌(ATCC-25922),以及革兰氏阳性菌粪肠球菌(再培养)和金黄色葡萄球菌(ATCC-25923)进行了所有化合物的评估。所有合成化合物均对新型隐球菌(再培养)、白色念珠菌(再培养)、黑曲霉、奥杜安小孢子菌(再培养)和烟曲霉(再培养)进行了体外抗真菌活性评估。
在抗菌筛选中,我们确定了这项研究中具有高度抗菌活性的药物,例如:革兰氏阴性菌筛选中,3g 对铜绿假单胞菌具有高度活性(MIC:0.25 μg/mL),而 3e 和 3h 对肺炎克雷伯菌的活性更强(MIC:2 μg/mL),此外,3g 对粪肠球菌的活性也更强(MIC:2 μg/mL),优于标准环丙沙星。在抗真菌活性方面,3b 对白色念珠菌的活性更强(MIC:0.25 μg/mL),3g(MIC:2 μg/mL)和 3h(MIC:4 μg/mL)对烟曲霉的活性更强,化合物 3c 对奥杜安小孢子菌的活性(MIC:4 μg/mL)高于克霉唑。分子对接研究也支持了新的发现,具有潜在抗菌活性的药物,化合物 3g、3b 和对照环丙沙星、克霉唑,再次通过 Autodock Vina 程序检查了 1U1Z 和 1AI9 蛋白。化合物 3g 在 1U1Z 蛋白中的结合亲和力(-8.4 kcal/mol)高于环丙沙星(-8.2 kcal/mol),化合物 3b 在 1AI9 蛋白中的结合亲和力(-8.8 kcal/mol)高于克霉唑(-6.8 kcal/mol)。
成功合成并表征了一组新型咪唑烷-2,4-二酮化合物 3a-h。抗菌活性筛选表明,所有化合物均具有抗菌活性。此外,研究的目标是成功地确定了一些有前途的分子,这些分子被证明是治疗细菌感染的潜在候选药物。